

**Gene 436 (2009), 90 – 100**

**The conserved Myc box 2 and Myc box 3 regions are important, but not essential, for Myc function *in vivo***

D.Schwinkendorf & P.Gallant<sup>1</sup>

Zoologisches Institut, Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland

<sup>1</sup> author for correspondence: gallant@zool.uzh.ch, +41446354812

**Running title:** *In vivo* structure-function analysis of Myc

**Keywords:** growth, apoptosis, transcription

doi:[10.1016/j.gene.2009.02.009](https://doi.org/10.1016/j.gene.2009.02.009)

**Abstract**

Myc proto-oncoproteins are important regulators of growth and proliferation in development. Their functions have been evolutionarily conserved from insects to vertebrates, although the sequence conservation is limited to a few short domains. Here, we analyze the requirement for the most highly conserved domains, called Myc boxes 2 and 3 (MB2 and MB3), and for the weakly conserved N-terminus for the biological activity of the single *Drosophila* Myc protein in the animal *in vivo*. We find that a Myc mutant lacking the N-terminus retains very little activity, whereas Myc transgenes carrying a deletion of MB3 have a moderately increased ability to promote growth and apoptosis; mutation of MB2 reduces transcriptional output and the biological activities of Myc. Surprisingly though, Myc without MB2 retains enough activity to partially rescue the lethality of a *Myc* null mutation. Thus, although MB2 and MB3 are highly conserved in evolution, loss of either domain has comparatively mild consequences on Myc activity *in vivo*.

## 1 Introduction

Myc has been identified as a proto-oncogene that is frequently mutated and overexpressed in human and animal cancers (reviewed by Oster *et al.*, 2002). During normal development and tissue homeostasis, Myc controls several cellular processes, most prominently growth, proliferation and apoptosis (de la Cova and Johnston, 2006; Pirity *et al.*, 2006). These different activities of Myc have been attributed to its ability to stimulate or repress the transcription of many target genes (reviewed by Grandori *et al.*, 2000; Amati *et al.*, 2001; Dang *et al.*, 2006). Up to 15% of all genes are modulated by Myc proteins (Fernandez *et al.*, 2003; Orian *et al.*, 2003), including genes transcribed by RNA polymerases I and III. However, most of its targets are only moderately affected by Myc (reviewed by Dang *et al.*, 2006). In addition, Myc has transcription-independent roles in the control of DNA replication (Dominguez-Sola *et al.*, 2007).

To molecularly understand how Myc controls its target genes and what might distinguish Myc from other transcription factors, several structure/function analyzes of Myc have been carried out. Myc's best understood domain, and the only one for which structural information is available (Nair and Burley, 2003), is the C-terminal basic-helix-loop-helix-leucine zipper region (BHLHZ) which serves as a dimerization interface with a protein called Max (Blackwood and Eisenman, 1991) and also mediates the contact of Myc:Max heterodimers with DNA. In addition, several other proteins have been shown to contact this C-terminus (reviewed by Cowling and Cole, 2006). This region is generally assumed to be essential for all of Myc's activities, although recent reports suggest the existence of some C-terminus independent functions of Myc (Cowling and Cole, 2007; Steiger *et al.*, 2008).

Myc's N-terminal 143 amino acids contain a transcriptional regulatory domain (Kato *et al.*, 1990) that interacts with different co-factors, such as TRRAP, a component of several histone acetyltransferase (HAT) complexes (McMahon *et al.*, 1998), the STAGA HAT (McMahon *et al.*, 2000; Liu *et al.*, 2003; Liu *et al.*, 2008), the DNA helicases Tip48 and Tip49 that also belong to different HAT and chromatin remodeling complexes (Wood *et al.*, 2000), and the elongation factor P-TEFb (Eberhardy and Farnham, 2002). Accordingly, a version of c-Myc that lacks the first 100 amino acids is inefficient in trans-

activating its target genes (Spotts *et al.*, 1997; Xiao *et al.*, 1998; Hirst and Grandori, 2000), and it is unable to transform primary cells in culture (Xiao *et al.*, 1998) or promote cell cycle re-entry of serum-starved fibroblasts (Hirst and Grandori, 2000). Surprisingly, though, such a truncated c-Myc protein retains substantial biological activity: it induces apoptosis in response to limitation of survival factors (Xiao *et al.*, 1998), stimulates the rate of proliferation of exponentially growing fibroblasts (Hirst and Grandori, 2000), even in the complete absence of endogenous c-Myc (Xiao *et al.*, 1998), and it can rescue a lethal mutation of the only *Drosophila* Myc gene, *dm*<sup>PG45</sup> (Benassayag *et al.*, 2005).

These properties contrast with those of a short motif called Myc box 2 (MB2) that is located between amino acids 128 and 143 in human c-Myc. The MB2 sequence is unique to Myc and evolutionarily highly conserved in all Myc proteins, down to invertebrates (reviewed in Gallant, 2006). Elimination of MB2 blocks or severely impairs all of Myc's biological activities that have been tested in cultured cells: the ability to promote cellular proliferation (Lee *et al.*, 1997; Conzen *et al.*, 2000; Hirst and Grandori, 2000; Kenney *et al.*, 2003), apoptosis (Evan *et al.*, 1992; Conzen *et al.*, 2000; Dugan *et al.*, 2002; Oster *et al.*, 2003; Cowling *et al.*, 2006), transformation (Sarid *et al.*, 1987; Stone *et al.*, 1987; Li *et al.*, 1994; Brough *et al.*, 1995; McMahon *et al.*, 1998; Conzen *et al.*, 2000; McMahon *et al.*, 2000; Nikiforov *et al.*, 2002; Oster *et al.*, 2003; Cowling *et al.*, 2006), and block differentiation (Freytag *et al.*, 1990). Furthermore, an MB2-mutant Myc very inefficiently rescues the proliferation defect of rat fibroblasts lacking endogenous c-Myc (Bush *et al.*, 1998; Xiao *et al.*, 1998; Nikiforov *et al.*, 2002; Oster *et al.*, 2003). The MB2 motif is required for the efficient interaction with several co-factors such as TRRAP and associated HATs (McMahon *et al.*, 1998; Bouchard *et al.*, 2001; Frank *et al.*, 2001; Nikiforov *et al.*, 2002), the HAT complex component BAF53 (Park *et al.*, 2002), TIP48 & TIP49 (Wood *et al.*, 2000), Skp2 (Kim *et al.*, 2003; von der Lehr *et al.*, 2003), and for the stimulation of pre-mRNA capping (Cowling and Cole, 2007). Nevertheless, it has been shown that a Myc mutant lacking MB2 still efficiently activates the expression of some target genes and artificial reporters (Kato *et al.*, 1990; Bello-Fernandez *et al.*, 1993; Li *et al.*, 1994; Brough *et al.*, 1995; Lee *et al.*, 1997; Xiao *et al.*, 1998; Nikiforov *et al.*, 2002), although many targets are only poorly activated by such a protein (Conzen *et al.*, 2000; Hirst

and Grandori, 2000; Bouchard *et al.*, 2001; Nikiforov *et al.*, 2002; Kenney *et al.*, 2003; Cowling *et al.*, 2006; Cowling and Cole, 2007). Such a Myc $\Delta$ MB2 mutant also fails to repress the genes that are normally down-regulated by wild type Myc (Li *et al.*, 1994; Lee *et al.*, 1997), including the *c-myc* locus itself (Penn *et al.*, 1990; Bush *et al.*, 1998; Oster *et al.*, 2003). Importantly, the biological function of the MB2 cannot be replaced by the strong transactivation domain of the viral transcription factor VP16 (Brough *et al.*, 1995).

Much less is known about the central 240 amino acids of Myc. This region is less conserved, with the exception of a motif called Myc box 3 (MB3) that is found in all Myc proteins from insects to vertebrates (note that the term "Myc box 3" has been applied to a different region by Herbst *et al.*, 2005; Cowling and Cole, 2006). Although MB3 resembles a PEST domain, and hence might be expected to contribute to the degradation of Myc protein, its deletion does not affect Myc's half-life (Herbst *et al.*, 2004); this region also does not seem to contribute to transcriptional regulation by Myc (Kato *et al.*, 1990). To date, MB3 has only been shown to be required for Myc's ability to transform certain cell types (the rat fibroblast line Rat1a and primary chicken hematopoietic cells; Heaney *et al.*, 1986; Biegelke *et al.*, 1987; Stone *et al.*, 1987). However, given its high evolutionary conservation, we consider it likely that MB3 fulfills some additional essential functions that may not be evident in cultured cells *in vitro* - and the same might possibly hold true for other conserved domains as well.

Therefore, we set out to address the importance of the conserved domains for Myc function *in vivo* in the context of intact tissues. We used *Drosophila melanogaster*, which contains a single Myc gene (*diminutive* or *dm*) that is functionally interchangeable with its vertebrate counterparts (Gallant *et al.*, 1996; Schreiber-Agus *et al.*, 1997; Trumpp *et al.*, 2001; Benassayag *et al.*, 2005). Mutations in *Myc* impair growth, such that flies carrying hypomorphic *Myc* alleles (e.g. *dm*<sup>P0</sup>) are delayed in their development and eclose as small adults (Johnston *et al.*, 1999), whereas *dm*<sup>4</sup> mutant flies (null for *Myc*) fail to grow as larvae and die within a few days of hatching (Pierce *et al.*, 2004; Pierce *et al.*, 2008; Steiger *et al.*, 2008). Conversely, overexpression of Myc promotes cellular growth (Johnston *et al.*, 1999), endoreplication (Maines *et al.*, 2004; Pierce *et al.*, 2004), and apoptosis (De La Cova *et al.*, 2004;

Montero et al., 2008). In the present study, we expressed wild type and mutant forms of Myc (carrying mutations in MB2, MB3, or the N-terminus) *in vivo*. These experiments revealed a strong requirement for the N-terminus for all Myc-dependent activities. Surprisingly, mutation of MB2 only weakened, but did not fully inactivate Myc function, such that an MB2-mutant form of Myc could rescue the survival of a sizable fraction of *Myc*-null mutant flies. Finally, deletion of MB3 only moderately affected several of Myc's activities *in vivo*.

## 2 Materials and Methods

### 2.1 Cloning and expression of Myc proteins

A cDNA for wild type Myc with a triple HA-epitope at its N-terminus (Bellosta et al., 2005) was cloned into a *pBS*-vector carrying a single  $\Phi$ C31 *attB* site, 5 *UAS* repeats, a *hsp70* basal promoter, the SV40 polyA signal, and *mini-white* as a marker (Bischof et al., 2007). By site-directed mutagenesis the following mutant derivatives were created (numbering relative to untagged Myc): Myc $\Delta$ N: lacking amino acids 1 – 65; MycMB2A: containing “AAAA” instead of “DCMW”; Myc $\Delta$ MB2: “GP” substituted for residues 68-84; Myc $\Delta$ MB3: “F” substituted for residues 405-422. The same cDNAs were also cloned directly under the control of the  $\alpha$ -*tubulin84B* promoter (see Bellosta et al., 2005) into an analogous *pBS*-vector lacking *UAS*- and *hsp70*-sequences. Full sequences are available upon request.

### 2.2 Drosophila lines

Transgenic flies were established by integrating the different *attB* plasmids into the *attP* landing site *zh-86Fb* (Bischof et al., 2007; <http://www.frontiers-in-genetics.org/>), and confirmed by PCR. Source of additional flies: GAL4 drivers (*Drosophila* stock center at Bloomington), *act-FRT-CD2-FRT-GAL4* (Neufeld et al., 1998), *GMR-FRT-w<sup>+</sup>-FRT-GAL4* (Brogiolo et al., 2001), *tub-FRT-Myc-FRT-GAL4* (De La Cova et al., 2004), *dm<sup>P0</sup>* (Johnston et al., 1999), *dm<sup>2</sup>* (Maines et al., 2004), *dm<sup>4</sup>* (Pierce et al., 2004), *dm<sup>4</sup> mnt<sup>l</sup>* (Pierce et al., 2008), *dm<sup>PL35</sup>* & *dm<sup>PG45</sup>* (Benassayag et al., 2005).

### 2.3 Western blots & immunocytochemistry

To document transgene expression *in vivo*, 20 wing imaginal discs of uncrowded wandering larvae carrying one copy of *tub-HAMyc<sup>mut</sup>* were lysed directly in Laemmli sample buffer and analyzed by SDS-PAGE and immunoblotting. Primary antibodies were: rabbit anti-HA epitope (Dunn Labortechnik GmbH), mouse anti- $\alpha$ -Tubulin (Sigma). Secondary antibodies were HRP-coupled anti-rabbit (GE

Healthcare) or anti-mouse (Jackson Immuno Research) and for detection the enhanced chemiluminescence kit (Amersham) was used.

For TUNEL staining of wing imaginal discs, wandering third instar larvae were fixed in 4% paraformaldehyde for 20', washed with 1x PBT (0.1% Tween-20 in PBS [130 mM NaCl, 7 mM Na<sub>2</sub>HPO<sub>4</sub>, 3 mM NaH<sub>2</sub>PO<sub>4</sub>]) for 20', post-fixed in ethanol/PBS (2:1) for 5' at -20° C, washed with 3 changes of 0.1% Tween-20/PBS over 15', pre-treated with 10 mM sodium citrate (pH 6) for 30' at 70° C, equilibrated in Equilibration Buffer (ApopTag Red In Situ Apoptosis Detection Kit, Chemicon) for 10', then incubated with TdT enzyme (Chemicon kit) for 1 h at 37° C, Stop/Wash Solution (Chemicon kit) for 10', Rhodamine-coupled anti-DIG antibodies (Chemicon kit) for 30', and 3 changes of 0.1% Tween-20/PBS (containing 0.5 µg/ml Hoechst 33342 for the first step).

For clonal area measurements, larvae carrying the *act-FRT-CD2-FRT-GAL4* construct, *UAS-GFP* and the appropriate *UAS-HAMyc<sup>mut</sup>* transgene, were heat-shocked for 10' at 37° C in a water bath (at 48h AED), dissected 73 h later (at the wandering stage), fixed in 4% paraformaldehyde for 20', and washed with 3 changes of PBT (containing 0.5 µg/ml Hoechst 33342 for the first step) over 60'.

Wing discs were dissected and mounted in Vectashield Mounting Medium (Vectashield), and photographed on a Leica DMRA compound microscope at a 10x ocular magnification and analyzed with Adobe Photoshop.

## 2.4 qRT-PCR

Larvae were grown under uncrowded conditions, heat-shocked at wandering stage for 2 h at 37°C in a water bath, collected 8 h later into liquid nitrogen, and stored at -80°. To extract RNA, 10 male whole larvae were homogenized in 1 ml TRIZOL (Invitrogen) with a Polytron tissue homogenizer, following the manufacturers instructions. Upon precipitation, RNA was redissolved in 20 µl RNase-free water and analyzed for its integrity on a Bioanalyzer (Agilent). Genomic DNA was eliminated using the Turbo DNase free kit (Ambion) and cDNAs were synthesized from 1 µg of template RNA using the Omniscript kit (Qiagen). Parallel control reactions containing only RNA provided templates for “-RT” samples.



Quantitative real-time PCR (qRT-PCR) reactions were performed in triplicates on an ABI7900 Real Time PCR Instrument (Applied Biosystems), using the SYBR Green PCR Master Mix (Applied Biosystems). Data were analyzed with SDS 2.0 software (Applied Biosystems) and Microsoft Excel, using the  $\Delta\Delta C_t$  method and the average of the expression levels of *actin5C*, *Rab6* and *Sec24* as internal reference for each biological sample, with the values for “MycWT” set to 100%.

Primer sequences: *Rab6*: 5'-TGCACGTGGCCAAGTCCTA & 5'-CAGCGAACGCGACTGCTA; *Sec24* 5'-CCACTCCCCTGCCATCCT & 5'-ACCCCAAACCCAGCAACA; *CG5033*: 5'-TAACCGCTCGGCTTTAATTCA & 5'-CCCTTGCTCTTGGAGAATGG. The remaining primers and the PCR conditions have been described (Steiger et al., 2008).

## 2.5 Analysis of adult flies

Flies were kept on standard *Drosophila* medium and test crosses performed in climate-controlled chamber at 25°.

Scanning electron microscope pictures were taken with a JEOL JSM-6360 LV microscope and a magnification of 180x. Flies were frozen at -20° C for at least one day, slowly defrosted at 0°C and directly used for electron microscopy. For determination of ommatidial size, the area of 20 centrally located ommatidia was determined from 5 flies of the same genotype using Adobe Photoshop. The same photomicrographs were also used to determine the total number of ommatidia per eye. Obvious fusions of two ommatidia were counted as two individual ommatidia.

To determine adult weights, 1-2 day adult flies were frozen at -20° C for at least one day, defrosted at room temperature and weighed on a Mettler Toledo MX5 micro balance.

### 3 Results

#### 3.1 Transactivation potential of *Myc* mutants

To investigate the *in vivo* roles of the most highly conserved domains of *Myc*, we mutated or deleted MB2, MB3 or the entire N-terminus and tagged the different variants with a triple HA-epitope at their N-termini (Fig. 1A). Transgenes coding for the different constructs were established using the  $\Phi$ C31 system for targeted transgenesis, thus ensuring equal mRNA expression levels for all mutants and eliminating potentially confounding integration site effects (Groth *et al.*, 2004; Venken *et al.*, 2006; Bischof *et al.*, 2007). Indeed, the different proteins were mostly expressed at similar levels (Fig. 1B), although repeated Western blots (n=12) revealed some variability in the levels of the different protein variants (with the  $\Delta$ MB3 mutant occasionally [n=4] accumulating to higher levels than the other forms). As a first step to characterize the biological activities of these mutants, we monitored their ability to activate established endogenous *Myc* targets in a *Myc*-null mutant background. For this purpose, the transgenes were first combined with the *Myc* null allele *dm<sup>4</sup>*, a “*tub-FRT-Myc-FRT-GAL4*” transgene (which drives ubiquitous expression of a *Myc*<sup>WT</sup> cDNA and thereby rescues the lethality of the *dm<sup>4</sup>* allele; Bellosta *et al.*, 2005) and *hs-FLP*. Following a massive heat-shock of 2 hours at 37°, virtually all cells have eliminated the rescuing *Myc* cDNA and express GAL4 instead (Hulf *et al.*, 2005), which in turn drives the expression of the UAS-controlled transgenes. Eight hours later (before any overt signs of apoptosis; data not shown), total RNA was isolated and analyzed for the abundance of *Myc* and selected target genes. By this time, the mRNA levels for *Myc* and its RNA polymerase 2 transcribed targets *Nnp1* and *CG5033* (Hulf *et al.*, 2005) have significantly diminished, whereas the RNA polymerase 3 transcribed *Myc* targets *tRNA<sup>Leu</sup>* and *snoRNA U3* (Steiger *et al.*, 2008) show considerable perdurance (see Sup. Fig. 1A, which also provides an independent partial repeat of Fig. 1C below). Introduction of *Myc* $\Delta$ N leads to little activation of these genes above background (Fig. 1C, compare with the “-” sample expressing no transgene), but *Myc* $\Delta$ MB2 partially activates Pol 2 transcribed *Myc* targets; *Myc* $\Delta$ MB3 is almost as active as *Myc*<sup>WT</sup> towards *Nnp1* and *CG5033*, but (like *Myc* $\Delta$ N and *Myc* $\Delta$ MB2) has strongly reduced activity towards the Pol 3

transcribed Myc targets. Similar effects were observed in S2 cells, where the transiently expressed MB2 and MB3 mutants were able to partially activate a Myc-dependent reporter, whereas Myc $\Delta$ N was inactive (Sup. Fig. 1B, C). Taken together, these data confirm that N-terminus and MB2 are important for Myc dependent transcription by Pol 2 and Pol 3 (consistent with published data for the vertebrate proteins), and they reveal that MB3 also has a role in transactivation, in particular for the activation of RNA polymerase 3. The molecular basis for this stronger effect on Pol 3 is unclear; the only Myc-interacting protein that is currently known to be specifically involved in Pol 3-dependent transcription in *Drosophila*, Brf (Steiger *et al.*, 2008), binds with similar efficiency to both Myc $\Delta$ MB3 and MycWT (data not shown).

### 3.2 Overexpression of Myc mutants in vivo

Myc proteins are important both for normal development and tissue homeostasis, when they are expressed at physiological levels, and in the etiology of tumors, where they are frequently overexpressed. While Myc's physiological activities can account for much of its potency as an oncoprotein, it is conceivable that Myc takes on additional, qualitatively different, functions when expressed at supra-physiological levels. For these reasons, we wanted to investigate the activities of our Myc mutants first in overexpression situations, and second in the presence of amorphic *Myc* alleles, where the ability of the mutant proteins to substitute for endogenous Myc could be probed.

First, we analyzed the ability of the different Myc mutants to promote growth upon overexpression. It has previously been shown that overexpression of MycWT under the control of *GMR-GAL4* strongly increases the size of adult ommatidia (Secombe *et al.*, 2007; Montero *et al.*, 2008; Steiger *et al.*, 2008); since this driver expresses GAL4 in eye imaginal discs from the late 3<sup>rd</sup> larval instar on, it mainly influences the final growth and differentiation phase of the eye cells, but not the proliferation of their precursors and the final number of ommatidia. Consistent with their transactivation abilities, the MB2 mutants are still able to promote growth, albeit to a lesser extent than MycWT, and Myc $\Delta$ N is inactive in this assay (Fig. 2A, B). Surprisingly, Myc $\Delta$ MB3 increases ommatidial size more than MycWT and additionally induces considerable roughness of the eye. Such a morphology (caused by a combination of

excessive growth and apoptosis) is also observed when MycWT is expressed at higher levels (Steiger et al., 2008), indicating that Myc $\Delta$ MB3 is more active than MycWT in this assay, as a consequence of increased specific activity and/or higher levels of Myc $\Delta$ MB3.

The different Myc mutants show similar growth-promoting abilities when over-expressed under the control of *ap-GAL4* in the dorsal compartment of wing imaginal discs. The resulting size difference between the dorsal and the ventral compartments results in a moderate ( $\Delta$ MB2, MB2A) or strong (WT) bending down of the adult wings (Fig. 2C). Myc $\Delta$ N again shows no activity, even though this bending provides a very sensitive read-out for growth inducers (see Montagne et al., 1999). Myc $\Delta$ MB3 reveals other phenotypes (Fig. 2C) that can also be observed upon overexpression of a different, stronger MycWT transgene (e.g. dissociation of the dorsal and ventral wing surface, necrotic patches; data not shown), and that suggest that the Myc-induced excessive apoptosis overwhelms its growth-promoting ability. Indeed, TUNEL staining of 3<sup>rd</sup> instar larval wing discs (Fig. 3) reveals that all Myc proteins except for Myc $\Delta$ N induce apoptosis (as previously reported for MycWT; Montero *et al.*, 2008), but that Myc $\Delta$ MB3 clearly has the highest activity. Thus, like in the eye, the Myc $\Delta$ MB3 transgene is more active than MycWT in the wing.

The experiments described so far document the effects of the different Myc mutants on final adult tissue size. To demonstrate directly to which extent Myc proteins promote the rate of cellular growth, we expressed the different proteins in clones of cells in wing imaginal discs carrying an “*act-FRT-stop-FRT-GAL4*” cassette, a *hs-FLP* transgene and a *UAS-GFP* marker. Overexpression clones were induced by a 10' heat-shock at 37°, which drives the expression of FLP recombinase leading to the activation of GAL4 in a few random cells of the disc, and analyzed 73 hours later (after 6 to 7 cell doublings). The coexpressed GFP allowed for the identification of the clones; since larval wing discs consist essentially of a monolayer of undifferentiated cells, the areas of such clones provide a good measure for their volume increase. Consistent with published observations (Johnston et al., 1999), MycWT overexpression strongly promotes clonal growth (Fig. 4A, B), and so does MycMB2A. As expected, Myc $\Delta$ N does not affect the

growth rate of these clones. However, Myc $\Delta$ MB3 significantly reduces clonal area, suggesting that its powerful pro-apoptotic ability (see Fig. 3) overcomes the proliferative capacity of these clones.

Taken together, the overexpression studies demonstrate that the N-terminus is essential for Myc's ability to promote growth, whereas a mutation or deletion of MB2 only moderately impairs Myc activity; loss of MB3 increases the biological activity of Myc (possibly in part by affecting the levels of Myc protein).

### 3.3 Rescue of Myc mutant eyes by Myc protein mutants

Normal eye development requires Myc, and hypomorphic or null alleles of *Myc* result in smaller eyes, composed of smaller and (for lethal alleles) fewer ommatidia (Bellosta *et al.*, 2005; Steiger *et al.*, 2008; Fig. 5). Therefore the eye constitutes a good organ for analyzing the normal biological activities of Myc proteins. To reveal the phenotype of such *Myc* mutant eyes without lowering Myc activity in the rest of the body (which would interfere with organismal viability), we combined the rescuing transgene “*tub-FRT-Myc-FRT-GAL4*” with “*ey-FLP*”, resulting in elimination of the *Myc* cDNA and concomitant expression of GAL4 in precursors of the eye and head capsule. The FLP-mediated replacement of Myc with GAL4 is highly efficient, as shown in Sup. Fig. 2. We used this system to express the different Myc variants in eyes that were wild type for Myc or carried the null allele *dm*<sup>4</sup>. Importantly, transgene expression in this assay is maintained from early development to the terminal differentiation phase, and therefore affects both the final number and size of the resulting ommatidia.

All Myc mutants significantly increase ommatidial size as compared to control, with the effects being largest in the *dm*<sup>4</sup> background that lacks endogenous *Myc* altogether (Fig. 5A, B). Even Myc $\Delta$ N, which was inactive in all other assays, increases ommatidial size by 10% in a *dm*<sup>+</sup> background; the difference to the GMR-driven overexpression experiment shown above is presumably due to the different expression dynamics of the two GAL4 drivers [*GMR* is not expressed in all cell types of the differentiating eye (Ellis *et al.*, 1993), but *tub* should be ubiquitously expressed; furthermore level and duration of GAL4 expression are likely to differ between the two systems]. The  $\Delta$ N mutant also significantly increases the

number of ommatidia in  $dm^4$  mutant eyes (Fig. 5C, compare “-“ and “ΔN”), thus demonstrating its activity both during the earlier proliferative and the later differentiation phase. Note that we would not expect any Myc mutant to increase the number of ommatidia in  $dm^+$  eyes, since Myc overexpression does not increase cell division rates in wild type cells (Johnston et al., 1999). Instead, expression of the other Myc forms slightly or significantly reduces the number of ommatidia in this assay, reflecting the pro-apoptotic activity of these proteins (Bellosta et al., 2005). As before, this effect is strongest for MycΔMB3, as can also be seen by the obvious roughness of the eyes expressing this mutant (Fig. 5A). Taken together, this experiment confirms the growth- and apoptosis-promoting capabilities of the different Myc mutants, and it shows that MycΔN also retains some activity.

### 3.4 Organismal rescue of Myc mutants

As a final, most stringent, functional assay we determined to which extent the different Myc mutants could drive the entire development. None of the Myc transgenes was able to rescue the lethal *Myc* alleles  $dm^2$  or  $dm^4$  when expressed under the control of the ubiquitous GAL4 drivers *arm*, *da*, or *tub*; presumably the resulting Myc expression was either too weak (with *arm*-GAL4) or too strong (when driven by *da*-GAL4 or *tub*-GAL4 in a wild type background both MycWT and MycΔMB3 caused dominant lethality). Efficient rescue of lethality (to more than 50%) was only observed with the enhancer trap allele  $dm^{PG45}$ , which is both mutant for *Myc* and expresses GAL4 in a *Myc*-like pattern (Benassayag et al., 2005), in combination with MycΔN, MycΔMB2 or MycMB2A, indicating that Myc mutants that lack either the N-terminus or MB2 retain sufficient activity to complement the low levels of endogenous Myc in the  $dm^{PG45}$  mutant. Neither MycWT nor MycΔMB3 efficiently rescued  $dm^{PG45}$ , consistent with previous reports that a *UAS-MycWT* transgene does not rescue this allele but instead causes dominant lethality in a  $dm^{PG45}/dm^+$  background (Benassayag et al., 2005), presumably because the GAL4/UAS system amplifies the transcriptional output of the *Myc* locus to lead to excessive expression of the UAS-transgene. An analogous amplification might explain the lethality of a *MycWT* transgene when expressed under the control of a *tub*-GAL4 driver, whereas a transgene expressing MycWT directly under *tubulin* control

causes no harm in flies and even rescues a *Myc* null mutant. Such considerations prompted us to generate a second series of transgenes, in which the expression of the different *Myc* mutants is controlled directly by  $\alpha$ -*tubulin* regulatory sequences; these transgenes were integrated in the same chromosomal location as before using the  $\Phi$ C31 system. All transgenes could be established, although *tub-Myc $\Delta$ MB3* showed some dominant lethality in a *dm*<sup>+</sup> background and could not be maintained as a homozygous line. Both *Myc*WT and *Myc $\Delta$ MB3* rescued the lethality of *dm*<sup>4</sup> mutant flies (Fig. 6A, B), although the resulting adults were smaller than control (Fig. 6A, C). Expression of *Myc $\Delta$ N* did not lead to any escapers, but much to our surprise, a substantial fraction of *Myc $\Delta$ MB2* expressing *dm*<sup>4</sup> flies (15% of the expected number) developed to term when 2 copies of the transgene were present and eclosed as normally patterned adults (Fig. 6). This fraction increases to 39% when the *Myc* antagonist *Mnt* is simultaneously mutated, i.e. in a *dm*<sup>4</sup> *mnt*<sup>1</sup> background, where *Myc* targets have been shown to be partially derepressed (Pierce et al., 2008). Thus, MB2 is not absolutely required to promote the full development from egg to adult, even in the absence of any endogenous *Myc* protein.

## 4 Discussion

### 4.1 *Myc box 2*

Myc proteins show a comparatively low overall sequence conservation between the most distant known family members from insects and vertebrates, but they all contain a short, highly conserved sequence motif, the Myc box 2 (MB2). The very fact that this domain is conserved suggests an indispensable function, and MB2 has indeed been shown to play an essential role in different tissue culture based assays. However, the variety of cell types that have been tested in tissue culture (most frequently fibroblasts), as well as the types of biological read-outs that have been used (typically proliferation, apoptosis or transformation), are both limited. As Myc interacts with many different transcriptional co-factors, we hypothesized that the proteins contacting MB2 might be important for the expression of only a subset of Myc's targets, or essential only in certain cell types, or required for only certain biological processes. By expressing MB2-mutant forms of Myc *in vivo*, we exposed the proteins to a variety of different contexts. We expected that the mutants would be inactive in most situations, but possibly retain some activity in a particular assay. Unexpectedly however, MB2 mutants showed an intermediate activity in all our assays (often close to that of MycWT). Most strikingly, Myc $\Delta$ MB2 was able to rescue mutant animals lacking all endogenous Myc, which would otherwise all have died during development. This finding suggests that MB2 does not contribute a qualitatively unique and essential function to Myc, but instead may act to enhance Myc's transcriptional output or modulate it in response to external signals. It further implies that no essential co-factor relies on MB2 for its interaction with Myc, either because no MB2-interacting protein is essential for Myc function, or because all MB2-interacting essential co-factors also contact Myc via additional redundant domains. At present we cannot address these possibilities experimentally, since no protein has been found to contact MB2 in *Drosophila*; two candidates we investigated (dGCN5 and Tip49/Pontin) bound Myc independently of the presence of MB2 (data not shown). Thus, we can only speculate about reasons for the partial dispensability of MB2; for example, the activation of a Myc target that normally relies on an MB2-dependent HAT might be partially taken over



by an MB2-independent HAT, or that such a *Myc* target gene might instead be activated by a histone acetylation-independent process, or that other targets might supplant the function of such genes. In either case, our observations provide an example of unexpected biological plasticity, considering the exceptional evolutionary conservation of this MB2.

#### 4.2 *N-terminus*

By comparison, the elimination of the entire N-terminus has substantially more severe effects. Nevertheless, the *Myc* $\Delta$ N protein (which corresponds to the naturally occurring c-MycS variant in vertebrates) clearly retains some activity. Similar to human c-MycS (Benassayag et al., 2005), *Myc* $\Delta$ N can rescue the lethality of the *dm*<sup>PG45</sup> allele; as *dm*<sup>PG45</sup> is a hypomorphic (albeit lethal) *Myc* allele, some *Myc* activity must still be present in these flies and might cooperate with *Myc* $\Delta$ N in this rescue. However, *Myc* $\Delta$ N also significantly enhances the size and number of ommatidia that lack *Myc* altogether (Fig. 5), demonstrating that this mutant has the ability to stimulate cellular growth and proliferation on its own (although, like c-MycS, it cannot induce apoptosis – Fig. 3). This growth effect is comparatively weak and not seen in other overexpression experiments, though, essentially confirming studies of vertebrate *Myc* that have assigned an important biological role to this part of the protein.

#### 4.3 *Myc box 3*

The function of the second highly conserved domain in *Myc*, MB3, is more ambiguous. MB3 resembles PEST motifs, but its deletion has no dramatic effect on *Myc* levels under normal culture conditions, suggesting that other evolutionary constraints are imposed on this domain. Indeed, the *Myc* $\Delta$ MB3 mutant has a lower transactivation potential than *Myc*WT, in particular towards Pol3 transcribed genes, raising the possibility that this domain contacts some co-activators (that remain to be identified). In light of its reduced transcriptional activity, it is surprising that *Myc* $\Delta$ MB3 is more potent than *Myc*WT in inducing apoptosis (in the developing wing) and growth (in the differentiating eye). At present we can only speculate that the deletion of MB3 might differentially affect the expression of certain *Myc* targets (as suggested by the stronger defect in activating Pol3 targets), and that certain *Myc* targets that are important

for the terminal size increase of ommatidia are still activated by this mutant (or that their expression is even enhanced at the expense of other targets). Such an “unbalanced” activation of Myc targets might also poise certain cells towards an apoptotic fate. In addition, we cannot exclude the possibility that a slightly increased stability of the Myc $\Delta$ MB3 mutant may also contribute to its increased *in vivo* activities. Finally, it should be noted that the sequence coding for MB3 straddles the junction between exons 2 and 3 in all *Myc* genes (Fig. 1A), raising the possibility that some splice signals or another unknown structure of the Myc gene contribute to the evolutionary maintenance of MB3 – or alternatively, that the conservation of MB3 sequences has concomitantly fixed the exon boundaries in *Myc*.

## **5 Acknowledgements**

We thank D.Steiger for comments on the manuscript, Regina Perez for technical assistance, and J.Bischof, K.Basler, H.Stocker, E.Hafen for flies. This research was supported by a grant from the SNF.

## 6 References

- Amati, B., Frank, S.R., Donjerkovic, D. and Taubert, S. Function of the c-Myc oncoprotein in chromatin remodeling and transcription. *Biochim Biophys Acta* 1471 (2001), pp. M135-45.
- Bello-Fernandez, C., Packham, G. and Cleveland, J.L. The Ornithine Decarboxylase Gene is a Transcriptional Target of c-Myc. *Proceedings of the National Academy of Sciences* 90 (1993), pp. 7804-7808.
- Bellosta, P., Hulf, T., Diop, S.B., Usseglio, F., Pradel, J., Aragnol, D. and Gallant, P. Myc interacts genetically with Tip48/Reptin and Tip49/Pontin to control growth and proliferation during *Drosophila* development. *Proc Natl Acad Sci U S A* 102 (2005), pp. 11799-804.
- Benassayag, C., Montero, L., Colombie, N., Gallant, P., Cribbs, D. and Morello, D. Human c-Myc isoforms differentially regulate cell growth and apoptosis in *Drosophila melanogaster*. *Mol Cell Biol* 25 (2005), pp. 9897-909.
- Biegalka, B.J., Heaney, M.L., Bouton, A., Parsons, J.T. and Linial, M. MC29 deletion mutants which fail to transform chicken macrophages are competent for transformation of quail macrophages. *J Virol* 61 (1987), pp. 2138-42.
- Bischof, J., Maeda, R.K., Hediger, M., Karch, F. and Basler, K. An optimized transgenesis system for *Drosophila* using germ-line-specific phiC31 integrases. *Proc Natl Acad Sci U S A* 104 (2007), pp. 3312-7.
- Blackwood, E.M. and Eisenman, R.N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. *Science* 251 (1991), pp. 1211-7.
- Bouchard, C., Dittrich, O., Kiermaier, A., Dohmann, K., Menkel, A., Eilers, M. and Luscher, B. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. *Genes Dev* 15 (2001), pp. 2042-7.
- Brogiolo, W., Stocker, H., Ikeya, T., Rintelen, F., Fernandez, R. and Hafen, E. An evolutionarily conserved function of the *Drosophila* insulin receptor and insulin-like peptides in growth control. *Current Biology* 11 (2001), pp. 213-21.
- Brough, D.E., Hofmann, T.J., Ellwood, K.B., Townley, R.A. and Cole, M.D. An essential domain of the c-myc protein interacts with a nuclear factor that is also required for E1A-mediated transformation. *Molecular & Cellular Biology* 15 (1995), pp. 1536-44.
- Bush, A., Mateyak, M., Dugan, K., Obaya, A., Adachi, S., Sedivy, J. and Cole, M. c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. *Genes & Development* 12 (1998), pp. 3797-802.
- Conzen, S.D., Gottlob, K., Kandel, E.S., Khanduri, P., Wagner, A.J., O'Leary, M. and Hay, N. Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis. *Mol Cell Biol* 20 (2000), pp. 6008-18.
- Cowling, V.H., Chandriani, S., Whitfield, M.L. and Cole, M.D. A conserved Myc protein domain, MBIV, regulates DNA binding, apoptosis, transformation, and G2 arrest. *Mol Cell Biol* 26 (2006), pp. 4226-39.
- Cowling, V.H. and Cole, M.D. Mechanism of transcriptional activation by the Myc oncoproteins. *Seminars in Cancer Biology* 16 (2006), p. 242.
- Cowling, V.H. and Cole, M.D. The Myc Transactivation Domain Promotes Global Phosphorylation of the RNA Polymerase II Carboxy-Terminal Domain Independently of Direct DNA Binding. *Mol. Cell. Biol.* 27 (2007), pp. 2059-2073.
- Dang, C.V., O'Donnell, K.A., Zeller, K.I., Nguyen, T., Osthus, R.C. and Li, F. The c-Myc target gene network. *Seminars in Cancer Biology* 16 (2006), p. 253.
- De La Cova, C., Abril, M., Bellosta, P., Gallant, P. and Johnston, L.A. *Drosophila* myc regulates organ size by inducing cell competition. *Cell* 117 (2004), pp. 107-16.
- de la Cova, C. and Johnston, L.A. Myc in model organisms: A view from the flyroom. *Seminars in Cancer Biology* 16 (2006), p. 303.

- Dominguez-Sola, D., Ying, C.Y., Grandori, C., Ruggiero, L., Chen, B., Li, M., Galloway, D.A., Gu, W., Gautier, J. and Dalla-Favera, R. Non-transcriptional control of DNA replication by c-Myc. *Nature* 448 (2007), pp. 445-51.
- Dugan, K.A., Wood, M.A. and Cole, M.D. TIP49, but not TRRAP, modulates c-Myc and E2F1 dependent apoptosis. *Oncogene* 21 (2002), pp. 5835-43.
- Eberhardy, S.R. and Farnham, P.J. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. *J Biol Chem* 277 (2002), pp. 40156-62.
- Ellis, M.C., O'Neill, E.M. and Rubin, G.M. Expression of Drosophila glass protein and evidence for negative regulation of its activity in non-neuronal cells by another DNA-binding protein. *Development* 119 (1993), pp. 855-65.
- Evan, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood, T.D., Land, H., Brooks, M., Waters, C.M., Penn, L.Z. and Hancock, D.C. Induction of apoptosis in fibroblasts by c-myc protein. *Cell* 69 (1992), pp. 119-28.
- Fernandez, P.C., Frank, S.R., Wang, L., Schroeder, M., Liu, S., Greene, J., Cocito, A. and Amati, B. Genomic targets of the human c-Myc protein. *Genes Dev* 17 (2003), pp. 1115-29.
- Frank, S.R., Schroeder, M., Fernandez, P., Taubert, S. and Amati, B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. *Genes Dev* 15 (2001), pp. 2069-82.
- Freytag, S.O., Dang, C.V. and Lee, W.M. Definition of the activities and properties of c-myc required to inhibit cell differentiation. *Cell Growth Differ* 1 (1990), pp. 339-343.
- Gallant, P. Myc / Max / Mad in invertebrates - the evolution of the Max network CTMI 302 (2006), pp. 237-254.
- Gallant, P., Shii, Y., Cheng, P.F., Parkhurst, S.M. and Eisenman, R.N. Myc and Max homologs in Drosophila. *Science* 274 (1996), pp. 1523-7.
- Grandori, C., Cowley, S.M., James, L.P. and Eisenman, R.N. The Myc/Max/Mad network and the transcriptional control of cell behavior. *Annu Rev Cell Dev Biol* 16 (2000), pp. 653-99.
- Groth, A.C., Fish, M., Nusse, R. and Calos, M.P. Construction of transgenic Drosophila by using the site-specific integrase from phage phiC31. *Genetics* 166 (2004), pp. 1775-82.
- Heaney, M.L., Pierce, J. and Parsons, J.T. Site-directed mutagenesis of the gag-myc gene of avian myelocytomatosis virus 29: biological activity and intracellular localization of structurally altered proteins. *Journal of Virology* 60 (1986), pp. 167-76.
- Herbst, A., Hemann, M.T., Tworowski, K.A., Salghetti, S.E., Lowe, S.W. and Tansey, W.P. A conserved element in Myc that negatively regulates its proapoptotic activity. *EMBO Rep* 6 (2005), pp. 177-83.
- Herbst, A., Salghetti, S.E., Kim, S.Y. and Tansey, W.P. Multiple cell-type-specific elements regulate Myc protein stability. *Oncogene* 23 (2004), pp. 3863-71.
- Hirst, S.K. and Grandori, C. Differential activity of conditional MYC and its variant MYC-S in human mortal fibroblasts. *Oncogene* 19 (2000), pp. 5189-97.
- Hulf, T., Bellosta, P., Furrer, M., Steiger, D., Svensson, D., Barbour, A. and Gallant, P. Whole-genome analysis reveals a strong positional bias of conserved dMyc-dependent E-boxes. *Mol Cell Biol* 25 (2005), pp. 3401-10.
- Johnston, L.A., Prober, D.A., Edgar, B.A., Eisenman, R.N. and Gallant, P. Drosophila myc regulates cellular growth during development. *Cell* 98 (1999), pp. 779-790.
- Kato, G.J., Barrett, J., Villa, G.M. and Dang, C.V. An amino-terminal c-myc domain required for neoplastic transformation activates transcription. *Molecular & Cellular Biology* 10 (1990), pp. 5914-20.
- Kenney, A.M., Cole, M.D. and Rowitch, D.H. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. *Development* 130 (2003), pp. 15-28.
- Kim, S.Y., Herbst, A., Tworowski, K.A., Salghetti, S.E. and Tansey, W.P. Skp2 regulates Myc protein stability and activity. *Mol Cell* 11 (2003), pp. 1177-88.

- Lee, T.C., Li, L.H., Philipson, L. and Ziff, E.B. Myc represses transcription of the growth arrest gene *gas1*. *Proceedings of the National Academy of Sciences of the United States of America* 94 (1997), pp. 12886-12891.
- Li, L.H., Nerlov, C., Prendergast, G., MacGregor, D. and Ziff, E.B. c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. *Embo Journal* 13 (1994), pp. 4070-9.
- Liu, X., Tesfai, J., Evrard, Y.A., Dent, S.Y. and Martinez, E. c-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation. *J Biol Chem* 278 (2003), pp. 20405-12.
- Liu, X., Vorontchikhina, M., Wang, Y.-L., Faiola, F. and Martinez, E. STAGA Recruits Mediator to the MYC Oncoprotein To Stimulate Transcription and Cell Proliferation. *Mol. Cell. Biol.* 28 (2008), pp. 108-121.
- Maines, J.Z., Stevens, L.M., Tong, X. and Stein, D. Drosophila dMyc is required for ovary cell growth and endoreplication. *Development* 131 (2004), pp. 775-86.
- McMahon, S.B., Van, B.H., Dugan, K.A., Copeland, T.D. and Cole, M.D. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. *Cell* 94 (1998), pp. 363-74.
- McMahon, S.B., Wood, M.A. and Cole, M.D. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. *Molecular & Cellular Biology* 20 (2000), pp. 556-562.
- Montagne, J., Stewart, M.J., Stocker, H., Hafen, E., Kozma, S.C. and Thomas, G. Drosophila S6 kinase: A regulator of cell size. *Science*. 285 (1999), pp. 2126-2129.
- Montero, L., Müller, N. and Gallant, P. Induction of apoptosis by Drosophila Myc. *Genesis* 46 (2008), pp. 104-111.
- Nair, S.K. and Burley, S.K. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. *Cell* 112 (2003), pp. 193-205.
- Neufeld, T.P., de la Cruz, A.F., Johnston, L.A. and Edgar, B.A. Coordination of growth and cell division in the Drosophila wing. *Cell* 93 (1998), pp. 1183-93.
- Nikiforov, M.A., Chandriani, S., Park, J., Kotenko, I., Matheos, D., Johnsson, A., McMahon, S.B. and Cole, M.D. TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins. *Mol Cell Biol* 22 (2002), pp. 5054-63.
- Orian, A., Van Steensel, B., Delrow, J., Bussemaker, H.J., Li, L., Sawado, T., Williams, E., Loo, L.W., Cowley, S.M., Yost, C., Pierce, S., Edgar, B.A., Parkhurst, S.M. and Eisenman, R.N. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. *Genes Dev* 17 (2003), pp. 1101-14.
- Oster, S.K., Ho, C.S., Soucie, E.L. and Penn, L.Z. The myc oncogene: MarvelouslyY Complex. *Adv Cancer Res* 84 (2002), pp. 81-154.
- Oster, S.K., Mao, D.Y., Kennedy, J. and Penn, L.Z. Functional analysis of the N-terminal domain of the Myc oncoprotein. *Oncogene* 22 (2003), pp. 1998-2010.
- Park, J., Wood, M.A. and Cole, M.D. BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic transformation. *Mol Cell Biol* 22 (2002), pp. 1307-16.
- Penn, L.J., Brooks, M.W., Laufer, E.M., Littlewood, T.D., Morgenstern, J.P., Evan, G.I., Lee, W.M. and Land, H. Domains of human c-myc protein required for autosuppression and cooperation with ras oncogenes are overlapping. *Mol. Cell. Biol.* 10 (1990), pp. 4961-4966.
- Pierce, S.B., Yost, C., Anderson, S.A.R., Flynn, E.M., Delrow, J. and Eisenman, R.N. Drosophila growth and development in the absence of dMyc and dMnt. *Developmental Biology* 315 (2008), p. 303.
- Pierce, S.B., Yost, C., Britton, J.S., Loo, L.W., Flynn, E.M., Edgar, B.A. and Eisenman, R.N. dMyc is required for larval growth and endoreplication in Drosophila. *Development* 131 (2004), pp. 2317-27.
- Pirity, M., Blanck, J.K. and Schreiber-Agus, N. Lessons learned from Myc/Max/Mad knockout mice. *Curr Top Microbiol Immunol* 302 (2006), pp. 205-34.

- Sarid, J., Halazonetis, T.D., Murphy, W. and Leder, P. Evolutionarily conserved regions of the human c-myc protein can be uncoupled from transforming activity. *Proceedings of the National Academy of Sciences of the United States of America* 84 (1987), pp. 170-3.
- Schreiber-Agus, N., Stein, D., Chen, K., Goltz, J.S., Stevens, L. and DePinho, R.A. *Drosophila* Myc is oncogenic in mammalian cells and plays a role in the diminutive phenotype. *Proc Natl Acad Sci U S A* 94 (1997), pp. 1235-40.
- Secombe, J., Li, L., Carlos, L. and Eisenman, R.N. The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. *Genes Dev* 21 (2007), pp. 537-51.
- Spotts, G.D., Patel, S.V., Xiao, Q.R. and Hann, S.R. Identification of downstream-initiated c-myc proteins which are dominant-negative inhibitors of transactivation by full-length c-myc proteins. *Molecular & Cellular Biology* 17 (1997), pp. 1459-1468.
- Steiger, D., Furrer, M., Schwinkendorf, D. and Gallant, P. Max-independent functions of Myc in *Drosophila*. *Nature Genetics* 40 (2008), pp. 1084-1091.
- Stone, J., de, L.T., Ramsay, G., Jakobovits, E., Bishop, J.M., Varmus, H. and Lee, W. Definition of regions in human c-myc that are involved in transformation and nuclear localization. *Molecular & Cellular Biology* 7 (1987), pp. 1697-709.
- Trumpp, A., Refaeli, Y., Oskarsson, T., Gasser, S., Murphy, M., Martin, G.R. and Bishop, J.M. c-Myc regulates mammalian body size by controlling cell number but not cell size. *Nature* 414 (2001), pp. 768-73.
- Venken, K.J.T., He, Y., Hoskins, R.A. and Bellen, H.J. P[acman]: A BAC Transgenic Platform for Targeted Insertion of Large DNA Fragments in *D. melanogaster*. *Science* 314 (2006), pp. 1747-1751.
- von der Lehr, N., Johansson, S., Wu, S., Bahram, F., Castell, A., Cetinkaya, C., Hydbring, P., Weidung, I., Nakayama, K., Nakayama, K.I., Soderberg, O., Kerppola, T.K. and Larsson, L.G. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. *Mol Cell* 11 (2003), pp. 1189-200.
- Wood, M.A., McMahon, S.B. and Cole, M.D. An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. *Mol Cell* 5 (2000), pp. 321-30.
- Xiao, Q., Claassen, G., Shi, J., Adachi, S., Sedivy, J. and Hann, S.R. Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. *Genes & Development* 12 (1998), pp. 3803-8.

## Figure legends

**Figure 1. Transcriptional activity of Myc mutants.** *A*, schematic representation of the Myc mutants used in this work. All constructs contain an N-terminal triple HA-tag, with the coordinates referring to the untagged Myc. The MB2 and MB3 sequences shown on the top are derived from human c-Myc (upper line) and *Drosophila* Myc (lower line); the dots in c-Myc represent a 6 residue acidic stretch missing in *Drosophila* Myc, and the vertical line shows the junction between exons 2 and 3 that is conserved in Myc genes. Uppercase letter designate identically conserved amino acids. In MycMB2A, the amino acids “DCMW” are replaced by “AAAA”. *B*, expression level of the HAMyc variants in wing imaginal discs. Wing imaginal discs of third instar larvae of the genotype “*y w; tub-HAMyc*” were collected at 5 days after egg deposition (AED) and processed for Western blot. Each lane contains the equivalent of 20 wing imaginal discs. The same blot was probed with anti-HA antibodies (top panel) to reveal HAMyc and with anti- $\alpha$ -Tubulin antibodies (bottom panel) as a loading control. *C*, expression of endogenous Myc targets in Myc-mutant larvae in response to the indicated transgenes. The Myc null mutation *dm<sup>4</sup>* was exposed, and the transgene expression triggered by a heat-shock. Shown are the averages ( $\pm$  standard deviations) of two biologically independent samples (except Myc $\Delta$ N: only one sample). Genotypes in C are “*w dm<sup>4</sup> tub>Myc>GAL4 hs-FLP/Y; X*”, where “X” corresponds to an empty vector transgene (sample “-“) or a *UAS-HAMyc<sup>mut</sup>* transgene as indicated.

**Figure 2: Effect of Myc overexpression on ommatidial size and wing shape.** *A*, scanning electron micrographs of representative eyes containing single *UAS*-transgenes with the indicated Myc mutants under the control of *GMR-GAL4*. The scale bars correspond to 100  $\mu$ m. *B*, average ommatidial area ( $\pm$  standard deviation) for the indicated genotypes (corresponding to the eyes in panel A), calculated from 20 centrally located ommatidia from 5 independent eyes per genotype. “\*\*\*” indicates genotypes whose ommatidia are significantly larger than “-“ ommatidia with  $p < 0.01$ . *C*, representative frontal views of adult wings of flies heterozygous for *ap-GAL4* (driving GAL4 expression in the dorsal wing compartment) and one *UAS*-transgene coding for the indicated Myc version.



**Figure 3: Induction of apoptosis by overexpressed Myc.** TUNEL-staining of representative third instar larval wing imaginal discs carrying one copy of *ap-GAL4* and one *UAS*-transgene coding for the indicated Myc version. The TUNEL-positive region in the panel showing a  $\Delta$ MB3 wing disc provides a good reflection of the GAL4 expressing domain.

**Figure 4: Stimulation of clonal growth by overexpressed Myc.** **A**, third instar larval wing imaginal discs with typical 73 hours old clones (marked in bright white) expressing GFP and the indicated Myc variant. To reveal nuclei, the discs have been stained with Hoechst 33342 dye. **B**, average clonal area from discs corresponding to the genotypes shown in panel A. Number of analyzed clones (in parentheses the corresponding genotype): 50 (-), 45 (WT), 42 ( $\Delta$ N), 53 (MB2A), 40 ( $\Delta$ MB3).

**Figure 5: Effects of continuous Myc expression on ommatidial size and number.** **A**, scanning electron micrographs of representative eyes of the indicated genotype. Sex chromosomes are “y w *tub-FRT-Myc stop-FRT-GAL4 ey-FLP/Y*” (labeled “*dm*<sup>+</sup>” on the left) or “w *dm*<sup>4</sup> *tub-FRT-Myc stop-FRT-GAL4 ey-FLP/Y*” (labeled “*dm*<sup>4</sup>”); all flies are males, i.e. contain no additional *dm*<sup>+</sup> allele; in addition, these flies carry one *UAS*-transgene coding for the Myc variant indicated below the picture. **B**, average ommatidial area ( $\pm$  standard deviation) for the indicated genotypes (corresponding to the eyes in panel A), calculated from 20 centrally located ommatidia from 5 independent eyes per genotype. The reference genotypes for the “*dm*<sup>+</sup>” and the “*dm*<sup>4</sup>” series are “*dm*<sup>+</sup>; -” and “*dm*<sup>4</sup>; -”, respectively; note that “*dm*<sup>4</sup>; -” ommatidia are 23% smaller than “*dm*<sup>+</sup>; -” ommatidia. All areas are significantly larger than the corresponding “-” control with  $p < 0.01$  (Students t-test), except for “*dm*<sup>+</sup>;  $\Delta$ N” where  $p = 0.03$ . **C**, average ommatidial number ( $\pm$  standard deviation) for the indicated genotypes (corresponding to the eyes in panel A). Asterisks indicate significance of difference to the corresponding “-” genotype, with  $p < 0.05$  (\*) and  $p < 0.01$  (\*\*).

**Figure 6: Rescue of a Myc-null mutation by the expression of Myc protein mutants under the direct control of the *tubulin*-promoter.** **A**, dissecting microscope pictures of rescued *Myc*-null mutant adult males expressing two copies of the indicated transgenes. **B**, relative survival rate for the indicated genotypes (the expected number of “w *dm*<sup>4</sup>/Y” or “w *dm*<sup>4</sup> *dmnt*<sup>1</sup>/Y” males carrying one or two copies of

the indicated “*tub-HAMyc<sup>mut</sup>*” transgenes was calculated from the number of recovered  $dm^4/dm^+$  heterozygous females from the same cross, and set to 100%). For each genotype 300-800 flies in total were scored (except for  $w\ dm^4/Y; tub-HAMyc\Delta MB3/+$ : 91 flies,  $w\ dm^4\ dmnt^1/Y; tub-HAMyc\Delta N$ : 64 flies,  $w\ dm^4\ dmnt^1/Y; tub-HAMyc\ WT$ : 229 flies), of which rescued *Myc*-mutant made up one quarter (one eighth for the *tub-HAMyc* $\Delta MB3$  transgenes). *C*, average weight of at least 13 male flies per genotype (except  $dm^4/Y; tub-HAMyc\Delta MB3/+$ : 8 flies); the error bars indicate standard deviation. The control genotype is “*y w*”.

# Figure 1






Figure 2





Figure 2




Figure 3

A





Figure 4

A



B




Figure 5







Figure 5

B



C




Figure 6






Figure 6

C



## **Supplemental Methods**

*Drosophila* S2 cells were cultured at 24°C in 1x Schneider's *Drosophila* medium (Gibco/BRL), supplemented with 10% fetal bovine serum, 1% Penicillin/Streptomycin. At 48 h after transfection, cells were harvested, washed with 1xPBS, lysed in Laemmli sample buffer and analyzed by SDS-PAGE and immunoblotting.

Reporter assays were carried out as previously described (Hulf et al. 2005). Briefly,  $1.3 \times 10^6$  cells/well of a 24-well cell culture plate were transfected with 0.65 ml serum-free medium containing 4.2  $\mu$ l cellfectin (Invitrogen), 0.08  $\mu$ g dsRNA targeting the 5' UTR of *Myc* (not recognizing the HAMyc-constructs), and 2.6  $\mu$ g plasmid DNA (consisting of a 1:1 mix of “CG5033<sup>wt</sup>-*Renilla* luciferase” and “CG5033 <sup>$\Delta$ Ebox</sup>-firefly luciferase” reporters, *tub-GAL4* and *UAS*-plasmids). After 15-16 h, 0.65 ml complete media was added; 24h later, cells were washed in 1xPBS, lysed in 1x Passive Lysis Buffer (Dual-Luciferase kit, Promega), and relative reporter expression determined on a Wallac luminometer.

## **Supplemental figure legends**

**Supplemental figure 1: Transcriptional activity of Myc variants in S2 cells and *in vivo*.** **A**, expression of endogenous Myc targets in *Myc*-mutant larvae in response to the indicated transgenes. Analogous experiment to the one shown in Fig. 1C (shown are averages  $\pm$  standard deviations of two additional biologically independent samples). The “no hs” samples contain *UAS-HAMycWT* but did not receive any heat-shock; the other samples are as indicated in the legend to Fig. 1C. **B**, Western blot of *Drosophila* S2 cells transiently transfected with *UAS*-plasmids coding for the indicated HAMyc variants together with a *tub-GAL4* plasmid. The cells were lysed at 48 hours after transfection. The same blot was probed with anti-HA antibodies (top panel) to reveal HAMyc and with anti- $\alpha$ -Tubulin antibodies (bottom panel) as a loading control. **C**, Effect of Myc variants on a reporter gene in S2 cells. Endogenous Myc was down-regulated with RNAi in S2 cells and the indicated Myc mutants were expressed instead. The graph shows the relative activity of the co-transfected luciferase reporter (*Renilla* luciferase activity, controlled by the wild type CG5033 promoter, divided by firefly luciferase activity, controlled by a

mutant *CG5033* promoter lacking the sole Myc binding site), with the relative activity of MycWT set to 100%; shown are the averages ( $\pm$  standard deviations) of 2 independent transfections from a representative experiment.

**Supplemental Figure 2: Efficiency of the *ey*-FLP system.** Red ommatidia in either panel retain the “*FRT-w<sup>+</sup> stop-FRT*” cassette and express the rescuing Myc cDNA, whereas the white ommatidia lack this cassette and the Myc cDNA, and hence expose the *dm<sup>4</sup>* mutant. This picture also reveals the eye size reduction caused by the loss of *Myc*. Genotypes: 1, “*w dm<sup>4</sup> tub-FRT-Myc stop-FRT-GAL4 ey-FLP/Y; GMR-FRT-w<sup>+</sup> stop-FRT-GAL4/+*”; 2, “*w dm<sup>4</sup> tub-FRT-Myc stop-FRT-GAL4 hs-FLP/Y; GMR-FRT-w<sup>+</sup> stop-FRT-GAL4/+*”.

Figure S1






Figure S2

---

A

